UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004013
Receipt number R000004748
Scientific Title Brain magnetic resonance spectroscopic study among cancer patients with chemotherapy
Date of disclosure of the study information 2010/08/06
Last modified on 2012/09/20 14:51:38

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Brain magnetic resonance spectroscopic study among cancer patients with chemotherapy

Acronym

Brain magnetic resonance spectroscopic study among cancer patients with chemotherapy

Scientific Title

Brain magnetic resonance spectroscopic study among cancer patients with chemotherapy

Scientific Title:Acronym

Brain magnetic resonance spectroscopic study among cancer patients with chemotherapy

Region

Japan


Condition

Condition

breast cancer

Classification by specialty

Medicine in general Chest surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To examine effect of chemotherapy on neurochemicals among breast cancer patients

Basic objectives2

Others

Basic objectives -Others

To examine the effect of chemotherapy for quality of life

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes in density of GABA in brain

Key secondary outcomes

Changes in density of another amino acid in brain


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >

Gender

Male and Female

Key inclusion criteria

1.Patients with pathological diagnosis of breast cancer
2.Patients who are informed of their diagnosis
3.Patients with Performance status of 0-1
4.Patients was with full written consent
5.Patients who will undergo surgical operation
6.Patients will or will not be treated by adjuvant chemotherapy (doxorubicin and cyclophosphamide followed by a taxan)

Key exclusion criteria

1.Patients who is not able to understand this study because of dementia, delirium, or other cognitive disorder
2.Patients who is not able to understand this study because of major depression, schizophrenia, bipolar disorder or other psychiatric disorder
3.Patients for whom MRI is contraindicated
4.Patients with epilepsy, meningitis and neural degnerative disorder
5.Patients with brain metastasis
6.Patients with recurrent breast cancer
7.Patients with bilateral breast cancer
8.Patients with past history of any other cancer
9.Patients who have undergone chemotherapy before this study
10.Patients with serious somatic disease
11.Patients who are judged to be inappropriate for this study by their physician in charge

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Asao Ogawa

Organization

Reserch Center for Innovative Oncology National Cancer Center Hospital East

Division name

Psycho-Oncology Division

Zip code


Address

6-5-1,Kashiwanoha, Kashiwa, Chiba, Japan

TEL

04-7134-7013

Email



Public contact

Name of contact person

1st name
Middle name
Last name Asao Ogawa

Organization

Reserch Center for Innovative Oncology National Cancer Center Hospital East

Division name

Psycho-Oncology Division

Zip code


Address

6-5-1,Kashiwanoha, Kashiwa, Chiba, Japan

TEL

04-7134-7013

Homepage URL


Email

asogawa@east.ncc.go.jp


Sponsor or person

Institute

Reserch Center for Innovative Oncology National Cancer Center Hospital East

Institute

Department

Personal name



Funding Source

Organization

Grant from Health and Labor Sciences Reserch Grants, the third-term comprehensive control reserch for cancer

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 08 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2010 Year 07 Month 28 Day

Date of IRB


Anticipated trial start date

2010 Year 07 Month 01 Day

Last follow-up date

2012 Year 07 Month 01 Day

Date of closure to data entry

2012 Year 07 Month 01 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information

We will investigate relationship between chemotherapy and metabolism of amino acid in central nervous system.


Management information

Registered date

2010 Year 08 Month 06 Day

Last modified on

2012 Year 09 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004748


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name